COMPANY

Hillhurst Biopharmaceuticals

Keywords: neurology hematology sickle cell disease Parkinson's disease inhaled Sickle Cell Anemia Parkinson Disease HBI-002

Location: San Diego, CA · source · Oct 13, 2026

Profile checked Oct 10, 2026

Timeline

Jun 30, 2026 Trial start Phase 2: Low-dose Carbon Monoxide (HBI-002) Trial to Evaluate Safety, Tolerability, PK, and Biomarkers in Parkinson's Disease source ↗
Sep 16, 2025 Grant Government grant — SBIR: $961,240 (annual award, as published), announced Sep 16, 2025. Agency: NIH/NEI. Source: government award database. source ↗
Jul 29, 2025 Grant Government grant — SBIR: $999,718 (annual award, as published), announced Jul 29, 2025. Agency: NIH/NHLBI. Source: government award database. source ↗
Feb 15, 2025 Trial start Phase 2: A Safety, Efficacy, and Pharmacokinetic (PK) Study of HBI-002, an Oral Carbon Monoxide (CO) Therapeutic, in Subjects With Sickle Cell Disease (SCD) source ↗
Jul 25, 2022 Trial start Phase 1: A Study to Assess the Safety and Pharmacokinetics of HBI-002, an Oral Carbon Monoxide Therapeutic, in Healthy Volunteers source ↗

Dec 31, 2026 (ESTIMATED) · Phase 2 · Low-dose Carbon Monoxide (HBI-002) Trial to Evaluate Safety, Tolerability, PK, and Biomarkers in Parkinson's Disease · NCT07005180

Estimated primary completion per ClinicalTrials.gov. Dates move.

Last 2 years.

Sep 16, 2025 Government grant — SBIR: $961,240 (annual award, as published), announced Sep 16, 2025. Agency: NIH/NEI. Source: government award database. source ↗
Jul 29, 2025 Government grant — SBIR: $999,718 (annual award, as published), announced Jul 29, 2025. Agency: NIH/NHLBI. Source: government award database. source ↗

Record	Title	Phase	Status	Start	Primary completion
NCT07005180	Low-dose Carbon Monoxide (HBI-002) Trial to Evaluate Safety, Tolerability, PK, and Biomarkers in Parkinson's Disease	Phase 2	Recruiting	Jun 30, 2026	Dec 31, 2026 (estimated)
NCT06144749	A Safety, Efficacy, and Pharmacokinetic (PK) Study of HBI-002, an Oral Carbon Monoxide (CO) Therapeutic, in Subjects With Sickle Cell Disease (SCD)	Phase 2	Completed	Feb 15, 2025	Jun 30, 2026 (actual)
NCT03926819	A Study to Assess the Safety and Pharmacokinetics of HBI-002, an Oral Carbon Monoxide Therapeutic, in Healthy Volunteers	Phase 1	Completed	Jul 25, 2022	Apr 26, 2023 (actual)